Liminatus Pharma(NASDAQ) LIMNW

Liminatus Pharma, Inc. is an immuno-oncology firm based in La Palma, California, focused on developing innovative cancer treatments. The company is actively engaged in clinical trials to advance its therapeutic offerings in the biotechnology sector.

Products and Services

• Innovative immuno-oncology therapies targeting various cancer types
• Clinical trial management and research services
• Collaboration with healthcare institutions for drug development

Growth Outlook

• Significant investment in research and development to enhance product pipeline
• Potential for partnerships with major healthcare organizations
• Focus on expanding clinical trials to increase market presence

Financial Highlights

• Recent quarterly net income of -$1,123,714, reflecting ongoing investment in R&D
• Trailing twelve months (TTM) revenue of $0, indicating early-stage development
• Cash and cash equivalents of $1,907,674 as of March 31, 2026, providing operational liquidity

Liminatus Pharma, Inc. operates in a highly competitive biotechnology landscape, with a commitment to advancing cancer treatment through innovative therapies. The company's focus on research and development is crucial for its growth trajectory, as it seeks to establish a robust product pipeline. Despite reporting no revenue in recent quarters, the substantial cash reserves indicate a capacity to fund ongoing operations and clinical trials. Investors may find the potential for future partnerships and market expansion appealing as the company navigates its growth phase.